Sunday, October 5, 2025 10/5/2025

High-throughput immunoproteomics for cancer biomarker discovery

Award Number: U2CCA271903
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

High-throughput immunoproteomics for cancer biomarker discovery - Project Summary/Abstract The goal of the ASU Biomarker Characterization Center is to improve ovarian and lung cancer screening through the development of biologically-relevant circulating immune biomarkers. The scientific approach of our Center is based on several fundamental principles. First, that altered cancer protein expression, structure, and post- translational modifications induce host autoantibodies to create circulating biomarkers. Second, that alterations in microbial antigen expression (such as respiratory pathogens) also induce immunity, often detected in benign rather than malignant disease. Third, that the protein modifications, as well as the immune response to these neoantigenic structures, are heterogeneous between people, and that serologic biomarkers may complement circulating protein biomarkers. We will take a systems immunology approach to discover three types of antibodies, anti-microbial antibodies, autoantibodies and anti-aberrant glycoprotein antibodies. Our proposal builds on our extensive experiences with cancer biomarker discovery and immunoproteomics technology development. Our previous results on autoantibody biomarkers have been confirmed in blinded phase 2 multicenter validation studies and led to a CLIA-certified commercial blood test. Our results have shown that multiplexed panels of autoantibodies are required for adequate predictive value. With prior EDRN support, we have developed a set of innovative immunoproteomics technologies, namely high-density nucleic acid programmable protein array (HD-NAPPA), contra-capture protein array (CCPA) and multiplexed in solution protein array (MISPA), that, together with the largest full-length human and microbial gene collection at our DNASU plasmid repository, enable us to study antibodies against the full human proteome, microbial proteomes and the human O-glycoproteome for antibody biomarker signatures in cancer. Our Meso Scale Diagnostics (MSD) team has fielded over 3,000 instruments worldwide, and over 700 commercially available biomarker assay kits. Our expertise at serologic assay development was selected by Operation Warp Speed to use the V-PLEX® serology panels as the basis of its standard binding assays for immunogenicity assessments in all funded Phase III clinical trials of COVID vaccines. We will use our MSD MultiArray platform to migrate the top serologic and protein markers for their utility in our target clinical applications. We will collaborate with experts on lung and ovarian cancer screening at Vanderbilt University Medical Center, Boston University, MD Anderson Cancer Center, and German Cancer Research Center, who will also provide access to high-quality well-characterized samples to develop circulating biomarkers to enhance ovarian cancer screening or to distinguish benign from malignant pulmonary nodules. Adhering to the principles of PRoBE design, we will perform Phase I discovery by screening protein arrays with cancer patient and control sera for cancer or control-specific antibodies. Candidate biomarkers for both lung and ovarian cancers will undergo Phase 2 validation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $967,342 )
2025	2025	ARIZONA STATE UNIVERSITY	660 S MILL AVENUE STE 204	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	001	4	9/9/2025	NON-COMPETING CONTINUATION	$967,342
2025	2024	ARIZONA STATE UNIVERSITY	660 S MILL AVENUE STE 204	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	000	3	3/31/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $967,342

Issue Date FY: 2024 ( Subtotal = $858,891 )
2024	2024	ARIZONA STATE UNIVERSITY	660 S MILL AVENUE STE 204	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	001	3	8/29/2024	NON-COMPETING CONTINUATION	$858,891
2024	2024	ARIZONA STATE UNIVERSITY	660 S MILL AVENUE STE 204	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	002	3	9/13/2024	NON-COMPETING CONTINUATION	$0
2024	2023	ARIZONA STATE UNIVERSITY	660 S MILL AVENUE STE 204	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	000	2	2/8/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $858,891

Issue Date FY: 2023 ( Subtotal = $962,182 )
2023	2023	ARIZONA STATE UNIVERSITY	660 S MILL AVENUE STE 204	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	000	2	9/11/2023	NON-COMPETING CONTINUATION	$962,182
2023	2023	ARIZONA STATE UNIVERSITY	660 S MILL AVENUE STE 204	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	001	2	9/14/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $962,182

Issue Date FY: 2022 ( Subtotal = $710,300 )
2022	2022	ARIZONA STATE UNIVERSITY	660 S MILL AVE STE 312	TEMPE	AZ	85281	MARICOPA	USA	Cancer Detection and Diagnosis Research	000	1	8/22/2022	NEW	$710,300
														Subtotal = $710,300

Grand Total All Awards = $3,498,715

Top

All Categories

About

Search

Reports

Data Submission

Award Information

High-throughput immunoproteomics for cancer biomarker discovery

Award Number: U2CCA271903

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer